About Asterias Biotherapeutics (NYSEAMERICAN:AST)
Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
SectorBiotechnology & Medical Research - NEC
Trailing P/E Ratio-3.38461538461538
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-79.80%
Return on Assets-59.45%
Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) released its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.01. The biotechnology company earned $1.75 million during the quarter, compared to analysts' expectations of $2.81 million. Asterias Biotherapeutics had a negative net margin of 403.38% and a negative return on equity of 79.80%. View Asterias Biotherapeutics' Earnings History.
When will Asterias Biotherapeutics make its next earnings announcement?
Where is Asterias Biotherapeutics' stock going? Where will Asterias Biotherapeutics' stock price be in 2018?
4 analysts have issued twelve-month price objectives for Asterias Biotherapeutics' shares. Their predictions range from $6.00 to $12.00. On average, they anticipate Asterias Biotherapeutics' share price to reach $9.75 in the next year. View Analyst Ratings for Asterias Biotherapeutics.
What are Wall Street analysts saying about Asterias Biotherapeutics stock?
Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (1/19/2018)
- 2. HC Wainwright analysts commented, "We remind investors that the company continues to advance the SCiStar Phase 2 trial of AST-OPC1, its lead clinical program, which is enrolling both complete cervical SCI patients (AIS A classification), who have no sensory or motor function at the lowest sacral level on the ASIA impairment scale, and incomplete cervical SCI patients (AIS B classification), who retain some sensory function but no motor function at this level. Among the five cohorts slated to be treated in the trial, the first two have completed enrollment of three and six subjects respectively. Cohort 3, which comprises AIS-A patients treated with 20M cells, should generate six-month efficacy data in 3Q17. Cohort 4, which is composed of AIS- B patients, should also generate six-month efficacy data in late 3Q17. Finally, Cohort 5, which is to enroll five to eight AIS-B subjects for treatment with 20M cells per patient, could complete enrollment in 3Q17 with six-month data available in early 2018." (3/30/2017)
- 3. FBR & Co analysts commented, "We are transferring coverage of Asterias Biotherapeutics, Inc. (AST) and maintaining our Outperform rating, but we are lowering our price target to $6 (from $10) to reflect a more conservative view. AST is developing therapies in an area of immense promise that can change the practice of medicine. However, the emerging field of regenerative medicine using stem cell therapy is accompanied by increased regulatory and clinical risk. The company’s lead program (AST-OPC1) is a pluripotent stem cell platform, a cell line derived from embryonic stem cells. Pluripotent stem cells are “master cells” and have the potential to differentiate into any cell type, as well as reproduce indefinitely. AST’s pluripotent stem cells, AST-OPC1, are differentiated into oligodendrocyte progenitor cells, which are glial cells in the central nervous system. AST-OPC1 is being developed for spinal cord injuries (SCIs) and is in a Phase I/IIa trial testing higher doses for safety and efficacy. There is no cure or effective therapy approved for SCI that can rehabilitate patients." (3/7/2017)
Are investors shorting Asterias Biotherapeutics?
Asterias Biotherapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,915,560 shares, an increase of 11.9% from the January 12th total of 2,605,402 shares. Based on an average trading volume of 244,712 shares, the days-to-cover ratio is currently 11.9 days. Approximately 9.2% of the company's stock are short sold.
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include Sunesis Pharmaceuticals (SNSS), Nabriva Therapeutics (NBRV), Arsanis (ASNS), Palatin Technologies (PTN), Compugen (CGEN), Corvus Pharmaceuticals (CRVS), ArQule (ARQL), Galectin Therapeutics (GALT), Pluristem Therapeutics (PSTI), Merrimack Pharmaceuticals (MACK), Zynerba Pharmaceuticals (ZYNE), Silence Therapeutics (SLN), Regulus Therapeutics (RGLS), Checkpoint Therapeutics (CKPT), Organovo (ONVO), Oramed Pharmaceuticals (ORMP), Bioline RX (BLRX) and Bioventix (BVXP).
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the folowing people:
- Don M. Bailey, Chairman of the Board (Age 70)
- Michael H. Mulroy, President, Chief Executive Officer, Director (Age 51)
- Ryan Daniel Chavez, Chief Financial Officer, General Counsel (Age 40)
- Casey C. Case Ph.D., Senior Vice President - Research and Nonclinical Development (Age 59)
- Edward D. Wirth III, Chief Medical Officer (Age 50)
- Stephen L. Cartt, Director (Age 53)
- Alfred D. Kingsley, Director (Age 74)
- Aditya P. Mohanty, Director (Age 50)
- Robert W. Peabody CPA, Director (Age 60)
- Howard I. Scher, Director (Age 64)
Who owns Asterias Biotherapeutics stock?
Asterias Biotherapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.13%), Deutsche Bank AG (0.12%) and Millennium Management LLC (0.11%). Company insiders that own Asterias Biotherapeutics stock include Alfred D Kingsley, Edward Wirth, Katharine E Spink, Michael H Mulroy, Natale S Ricciardi, Richard T Lebuhn and Stephen Lahue Cartt. View Institutional Ownership Trends for Asterias Biotherapeutics.
Who bought Asterias Biotherapeutics stock? Who is buying Asterias Biotherapeutics stock?
Asterias Biotherapeutics' stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Virtu Financial LLC and Deutsche Bank AG. Company insiders that have bought Asterias Biotherapeutics stock in the last two years include Alfred D Kingsley, Michael H Mulroy, Natale S Ricciardi, Richard T Lebuhn and Stephen Lahue Cartt. View Insider Buying and Selling for Asterias Biotherapeutics.
How do I buy Asterias Biotherapeutics stock?
Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Asterias Biotherapeutics' stock price today?
One share of Asterias Biotherapeutics stock can currently be purchased for approximately $2.20.
How big of a company is Asterias Biotherapeutics?
Asterias Biotherapeutics has a market capitalization of $119.13 million.
How can I contact Asterias Biotherapeutics?
Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.
MarketBeat Community Rating for Asterias Biotherapeutics (AST)MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Asterias Biotherapeutics (NYSEAMERICAN:AST) Earnings History and Estimates Chart
Asterias Biotherapeutics (NYSEAMERICAN AST) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/14/2017||Q3 2017||($0.15)||($0.15)||$1.43 million||$1.69 million||View||N/A|
|8/14/2017||Q2 2017||($0.18)||($0.18)||$1.25 million||$0.32 million||View||N/A|
|5/11/2017||Q1 2017||($0.18)||($0.17)||$1.63 million||$2.01 million||View||N/A|
|3/28/2017||Q4||($0.17)||($0.18)||$2.81 million||$1.75 million||View||N/A|
|11/14/2016||Q316||($0.17)||($0.24)||$1.50 million||$2.10 million||View||N/A|
|8/15/2016||Q216||($0.19)||($0.12)||$1.14 million||$1.53 million||View||Listen|
|3/29/2016||Q415||($0.13)||($0.13)||$1.07 million||$0.61 million||View||Listen|
|8/10/2015||Q215||($0.11)||($0.10)||$0.10 million||$0.77 million||View||Listen|
|5/7/2015||($0.13)||($0.14)||$0.10 million||$0.78 million||View||N/A|
|11/10/2014||Q3 2014||($0.05)||$0.09 million||View||N/A|
|8/11/2014||Q2 2014||($0.09)||$0.02 million||View||N/A|
|5/12/2014||Q1 2014||($0.07)||$0.06 million||View||N/A|
Asterias Biotherapeutics (NYSEAMERICAN:AST) Earnings Estimates
2018 EPS Consensus Estimate: ($0.64)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Asterias Biotherapeutics (NYSEAMERICAN:AST)
No dividend announcements for this company have been tracked by MarketBeat.com
Asterias Biotherapeutics (NYSEAMERICAN AST) Insider Trading and Institutional Ownership History
Asterias Biotherapeutics (NYSEAMERICAN AST) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/25/2018||Michael H Mulroy||Insider||Buy||2,134||$2.34||$4,993.56|| |
|12/26/2017||Michael H Mulroy||Insider||Buy||2,247||$2.22||$4,988.34|| |
|11/27/2017||Michael H Mulroy||Insider||Buy||2,076||$2.41||$5,003.16|| |
|10/25/2017||Michael H Mulroy||Insider||Buy||1,939||$2.55||$4,944.45|| |
|9/25/2017||Michael H. Mulroy||Insider||Buy||1,537||$3.25||$4,995.25|| |
|1/9/2017||Edward Wirth||Insider||Sell||3,415||$4.60||$15,709.00||3,415|| |
|1/9/2017||Katharine E Spink||COO||Sell||4,781||$4.60||$21,992.60||4,781|| |
|10/6/2016||Edward Wirth||Insider||Sell||3,415||$4.12||$14,069.80|| |
|10/6/2016||Katharine E. Spink||COO||Sell||4,781||$4.11||$19,649.91|| |
|9/9/2016||Edward Wirth||Insider||Sell||14,760||$3.52||$51,955.20|| |
|9/9/2016||Katharine E. Spink||COO||Sell||19,336||$3.52||$68,062.72|| |
|6/30/2016||Stephen Lahue Cartt||CEO||Buy||10,000||$2.40||$24,000.00||260,000|| |
|6/29/2016||Richard T Lebuhn||Director||Buy||5,000||$2.38||$11,900.00||25,000|| |
|6/10/2016||Stephen Lahue Cartt||CEO||Buy||50,000||$2.93||$146,500.00||250,000|| |
|6/9/2016||Alfred D Kingsley||Director||Buy||4,000||$2.93||$11,720.00||9,000|| |
|5/13/2016||Natale S Ricciardi||Director||Buy||14,706||$3.39||$49,853.34||19,706|| |
|9/15/2015||Edward Wirth||insider||Sell||2,880||$6.00||$17,280.00|| |
|9/15/2015||Katharine E. Spink||COO||Sell||3,760||$6.00||$22,560.00|| |
|6/25/2015||Andrew Arno||Director||Buy||5,000||$4.32||$21,600.00|| |
|2/9/2015||Pedro Lichtinger||CEO||Buy||128,205||$3.90||$499,999.50|| |
|10/1/2014||Scarsdale Equities Llc||Major Shareholder||Buy||60,000||$5.93||$355,800.00|| |
Asterias Biotherapeutics (NYSEAMERICAN AST) News Headlines
|Asterias Biotherapeutics (AST) Earns Buy Rating from Analysts at B. Riley|
www.americanbankingnews.com - February 25 at 2:06 PM
|Benzinga's Top Upgrades, Downgrades For February 22, 2018 - Benzinga|
www.benzinga.com - February 22 at 3:38 PM
|Asterias Biotherapeutics Inc (AST) Receives Consensus Rating of "Hold" from Brokerages|
www.americanbankingnews.com - February 22 at 9:51 AM
|Notable Friday Option Activity: AST, WIFI, PTCT - Nasdaq|
www.nasdaq.com - February 17 at 3:37 PM
|Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer ... - GlobeNewswire (press release)|
globenewswire.com - February 17 at 3:37 PM
|Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program|
finance.yahoo.com - February 15 at 3:38 PM
|Asterias Biotherapeutics Inc (AST) Sees Significant Growth in Short Interest|
www.americanbankingnews.com - February 9 at 8:06 PM
|Short Interest in Asterias Biotherapeutics Inc (AST) Expands By 0.1%|
www.americanbankingnews.com - January 30 at 2:44 PM
|Asterias Biotherapeutics (AST) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - January 19 at 6:02 PM
|Short Interest in Asterias Biotherapeutics Inc (AST) Declines By 2.6%|
www.americanbankingnews.com - January 11 at 2:36 AM
|Asterias Biotherapeutics' (AST) "Buy" Rating Reaffirmed at HC Wainwright|
www.americanbankingnews.com - January 8 at 7:26 AM
|33 Stocks Moving In Thursday's Mid-Day Session | Benzinga - Benzinga|
www.benzinga.com - January 4 at 4:43 PM
|Asterias Biotherapeutics reports milestone targets for 2018 - Seeking Alpha|
seekingalpha.com - January 4 at 4:43 PM
|Asterias Biotherapeutics Reports Milestone Targets for 2018 - Nasdaq - Nasdaq|
www.nasdaq.com - January 4 at 3:43 PM
|Asterias Biotherapeutics Reports Milestone Targets for 2018|
finance.yahoo.com - January 4 at 10:07 AM
|ETFs with exposure to Asterias Biotherapeutics, Inc. : December 28, 2017|
finance.yahoo.com - December 28 at 4:25 PM
|Asterias Biotherapeutics Inc (AST) Short Interest Up 6.3% in December|
www.americanbankingnews.com - December 27 at 6:38 PM
|Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017|
finance.yahoo.com - December 27 at 12:57 PM
|Wired News – Asterias Reports Enrollment and Dosing of Last Subject in SciStar Trial In Treatment of Severe Spinal Cord Injury|
finance.yahoo.com - December 21 at 10:12 AM
|BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018 - Business Wire (press release)|
www.businesswire.com - December 20 at 3:42 PM
|BRIEF-Asterias Biotherapeutics Completes Enrollment Of Entire SCiStar Study|
www.reuters.com - December 19 at 4:40 PM
|Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study - Nasdaq|
www.nasdaq.com - December 19 at 10:15 AM
|Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study|
finance.yahoo.com - December 19 at 10:15 AM
|Asterias Biotherapeutics Inc (AST) Sees Large Decrease in Short Interest|
www.americanbankingnews.com - December 12 at 2:26 AM
|Asterias Biotherapeutics Inc (AST) Short Interest Up 4.9% in November|
www.americanbankingnews.com - November 27 at 7:48 PM
|Asterias Biotherapeutics Inc (AST) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - November 22 at 5:10 PM
|Asterias Biotherapeutics Inc (AST) Stock Rating Reaffirmed by HC Wainwright|
www.americanbankingnews.com - November 22 at 8:05 AM
|Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017 - GlobeNewswire (press release)|
globenewswire.com - November 16 at 9:25 PM
|Asterias Biotherapeutics to Present at Piper Jaffray Healthcare Conference on November 28, 2017|
finance.yahoo.com - November 16 at 4:24 PM
|ETFs with exposure to Asterias Biotherapeutics, Inc. : November 15, 2017|
finance.yahoo.com - November 16 at 11:33 AM
|Asterias Biotherapeutics posts 3Q loss|
finance.yahoo.com - November 16 at 11:33 AM
|Astur Gold Corp (AST) Sees Significant Decline in Short Interest|
www.americanbankingnews.com - November 14 at 12:02 AM
|Astur Gold Corp (AST) Scheduled to Post Earnings on Tuesday|
www.americanbankingnews.com - November 13 at 8:20 PM
Asterias Biotherapeutics (NYSEAMERICAN:AST) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Asterias Biotherapeutics (NYSEAMERICAN AST) Stock Chart for Sunday, February, 25, 2018